TAC101-CLDN18.2
claudin 18.2-positive solid tumors (e.g., gastric, pancreatic)
Phase 1/2Active
Key Facts
Indication
claudin 18.2-positive solid tumors (e.g., gastric, pancreatic)
Phase
Phase 1/2
Status
Active
Company
About Triumvira Immunologics
Triumvira Immunologics is pioneering a differentiated approach to engineered T cell therapy with its T cell Antigen Coupler (TAC) platform, which aims to activate T cells through a more natural signaling mechanism compared to CAR-T or TCR therapies. The company is in clinical development, with its lead candidate, TAC101-CLDN18.2, targeting claudin 18.2-positive solid tumors in a Phase 1/2 trial. Backed by strategic manufacturing partnerships and a focus on both solid and liquid tumors, Triumvira is positioning its technology as a potentially safer and more broadly applicable cell therapy platform for difficult-to-treat cancers.
View full company profile